Clinical trials: High Risk Localized Prostate Cancer, open to volunteers
Localized Prostate Carcinoma
Multi-omic Approach to Study HDR Brachytherapy for Favorable Risk and Low Tier Intermediate Risk Prostate Cancer
This is an observational single-center trial for patients with localized prostate cancer suitable for High Dose Rate (HDR) brachytherapy as monotherapy.
- Trial name
- BrachyTRACKS (NCT06200974)
- Testing
- High dose rate prostate brachytherapy
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- British Columbia Cancer Agency
Prostate Cancer (Adenocarcinoma)
Neoadjuvant High Dose Rate Brachytherapy Prior to Radical Prostatectomy in Patients With Prostate Cancer
This is a Phase I/II trial evaluating the effectiveness of adding neoadjuvant HDR-B prior to RALP for HR-PCa patients with selective AAB for decipher high risk or pathologically node positive patients.
- Trial name
- NCT07182279
- Testing
- Brachytherapy
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- The Methodist Hospital Research Institute
Prostate Cancer
Improving Engagement From Underserved Communities With Prostate Cancer Genetics Services
Earlier work explored barriers and facilitators to accessing prostate cancer screening, particularly in underserved communities, and provided valuable insights to build upon.
- Trial name
- INCLUDE PC (NCT07407686)
- Testing
- Surveys, Semi-structured interviews and focus groups
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Royal Marsden NHS Foundation Trust
Prostate Cancer
Image-guided, Tumor-focused Radiotherapy Treatment in Intermediate and High-risk Prostate Cancer
This is a phase II non-blinded randomized controlled trial of image-guided, tumor-focused radiotherapy in patients with intermediate- or high-risk prostate cancer planning to undergo definitive radiotherapy with or without…
- Trial name
- RadTARGET (NCT06990542)
- Testing
- Image-guided tumor-focused radiation therapy
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- University of California, San Diego
High-Risk Localized Prostate Cancer
PSMA-High: EBRT/ PSMA617/ ADT vs. EBRT/ ADT
This research is being done to find out if the study drug, 177Lu-PSMA-617, given before and during standard of care External Beam Radiation Therapy (EBRT) treatment, with a shorter course of Androgen Deprivation Therapy (ADT) (6…
- Trial name
- NCT07550517
- Testing
- EBRT + 6 mo ADT + 177Lu-PSMA-617, EBRT + 24 mo ADT
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate CA, Prostate Cancer (Adenocarcinoma)
Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer
The goal of this clinical trial is to determine the safety and feasibility of a new combination of darolutamide and relugolix as neoadjuvant therapy preceding radical prostatectomy (RP) for high-risk prostate cancer (PCa) in…
- Conditions
- Prostate CA, Prostate Cancer (Adenocarcinoma), Prostate Cancer Surgery
- Trial name
- NCT06631521
- Testing
- Darolutamide, Relugolix, Radical Prostatectomy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- AdventHealth
Prostate Adenocarcinoma, Stage IIIB Prostate Cancer AJCC v8
Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation
This phase II trial tests how well carboplatin before surgery works in treating patients with high-risk prostate cancer and an inherited BRCA1 or BRCA2 gene mutation.
- Conditions
- Prostate Adenocarcinoma, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8
- Trial name
- NCT05806515
- Testing
- Biospecimen Collection, Carboplatin, Chest Radiography
- Where
- 133 sites in United States
- Volunteers
- 44 people
- Sponsor
- SWOG Cancer Research Network
Prostate Cancer, Prostate Cancer (Adenocarcinoma)
ABlative Radiotherapy (for) Unfavorable Prostate Tumors 2.0
Published clinical evidence confirms that a single dose of 24 Gy provides unprecedented long-term local control in primary and metastatic prostate cancer with safe toxicity profiles, provided that exposure of surrounding healthy…
- Conditions
- Prostate Cancer, Prostate Cancer (Adenocarcinoma), Prostate Cancer Non-Metastatic
- Trial name
- ABRUPT 2 (NCT07407608)
- Testing
- SBRT, SDRT
- Where
- Italy
- Volunteers
- 58 people
- Sponsor
- University of Milano Bicocca
Prostate Cancer Patients
A Randomised Trial of Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) Plus Surgery for Prostate Cancer Patients
Current agents administered in therapeutic regimens of prostate cancer employ different mechanisms to eliminate neoplastic cells by inducing substantial apoptosis and causing tumor regression.
- Trial name
- NCT03258320
- Testing
- Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin
- Where
- 2 sites in China
- Volunteers
- 300 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Cancer Of Prostate
A Phase II Study Evaluating T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine PDS01ADC in Localized High and Intermediate Risk Prostate Cancer Treated With Androgen Deprivation Therapy
Background: Prostate cancer is often treated with radiation and ADT (ADT is androgen deprivation therapy). Up to 30% of these cancers recur within 5 years of treatment.
- Trial name
- NCT05361798
- Testing
- PDS01ADC, Stereotactic Body Radiation Therapy (SBRT)
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer
The primary objectives of this study are to evaluate the safety and tolerability of xaluritamig administered as monotherapy or in combination with an oral Gonadotropin-releasing Hormone (GnRH) antagonist in the neoadjuvant…
- Trial name
- NCT06613100
- Testing
- Xaluritamig, GnRH Antagonist
- Where
- 9 sites in United States, Germany
- Volunteers
- 40 people
- Sponsor
- Amgen
High Risk Prostate Carcinoma
Safety of Dose Escalation in Definitive Hypofractionated Radiation Therapy and Hormone Therapy With SpaceOAR TM for Patients With High - Risk Localized Prostate Cancer (DESAR-H)
Dose increase after injection of biodegradable material A safety study of high-risk prostate cancer patients who underwent low-fractionation curative radiation therapy and hormone therapy
- Trial name
- DESAR-H (NCT06461793)
- Testing
- Dose increase after injection of biodegradable material A safety study of high-risk prostate cancer patients
- Where
- South Korea
- Volunteers
- 33 people
- Sponsor
- Samsung Medical Center
Prostate Cancer
¹⁸F-PSMA-1007 PET-CT-Directed Focal Therapy for MRI-Invisible Prostate Cancer
Multiparametric magnetic resonance imaging (mpMRI) is the standard imaging modality for prostate cancer diagnosis and focal therapy planning.
- Trial name
- FOCUS-PSMA (NCT07788625)
- Testing
- Focal Therapy for Prostate Cancer
- Where
- Hong Kong
- Volunteers
- 60 people
- Sponsor
- The University of Hong Kong
Prostate Adenocarcinoma, Localized Prostate Carcinoma
Two-fraction HDR Monotherapy for Localized Prostate Cancer
This is a single center single arm prospective pilot study investigating the safety of high dose rate (HDR) brachytherapy as monotherapy delivered in 2 fractions 3 hours apart.
- Trial name
- NCT05665738
- Testing
- High Dose Rate Monotherapy
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of California, San Francisco
Prostate Cancer
Tumor-directed Radiation Therapy for Patients With the Highest Risk Category of Localized Prostate Cancer
HYPO-RT-PC boost is is an open-label, multicentre, phase II trial evaluating safety and efficacy of real-time image-guided tumor-directed ultra-hypofractionated radiation boost and lymph node irradiation for patients with…
- Trial name
- NCT06220435
- Testing
- Ultra-hypofractionated radiotherapy regimen.
- Where
- 2 sites in Sweden
- Volunteers
- 76 people
- Sponsor
- Region Skane
Prostate Cancer
Clinical Data Collection of Patients Treated With High Intensity Focused Ultrasound (HIFU) by the Focal One for Their Prostate Cancer.
The aim of the registry is to gather real-life data to evaluate the clinical performance and safety of medical devices in patients who have been treated with HIFU thank to the Focal One device for their prostate cancer.
- Trial name
- One registry (NCT07645872)
- Where
- 5 sites in France
- Volunteers
- 3,000 people
- Sponsor
- EDAP TMS S.A.
Prostate Cancer, Prostate Cancer (Diagnosis)
Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617
There is evidence that Actinium-225 Prostate-Specific Membrane Antigen (225Ac-PSMA) has a potentially higher level of efficacy than 177 Lutetium Prostate-Specific Membrane Antigen (177Lu-PSMA) as a radioligand therapy.
- Conditions
- Prostate Cancer, Prostate Cancer (Diagnosis), High-risk Prostate Cancer, Localized Prostate Carcinoma
- Trial name
- LUTACT (NCT07054346)
- Testing
- 177 Lutetium Prostate-Specific Membrane Antigen 617, Actinium-225 Prostate-Specific Membrane Antigen 617, Non-investigational, Prostatectomy
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Thomas Hope
Prostate Cancer
A Study of 2141-V11 in Combination With Standard Treatments in People With Prostate Cancer
The purpose of this study is to see whether combining 2141-V11 with various standard treatments is an effective treatment approach for prostate cancer. 2141-V11 works by activating the immune system to find and kill cancer cells.
- Trial name
- NCT06347705
- Testing
- 2141-V11 Antibody
- Where
- 7 sites in United States
- Volunteers
- 57 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostate Cancer
Neoadjuvant Intraprostatic OnabotulinumtoxinA Before Radical Prostatectomy for High-Risk Localized Prostate Cancer
This pilot randomized, single-blind, placebo-controlled study evaluates the feasibility, safety, and preliminary biological activity of neoadjuvant intraprostatic onabotulinumtoxinA (BOTOX®) administered before radical…
- Trial name
- NCT07796490
- Testing
- OnabotulinumtoxinA (BOTOX®)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- The Methodist Hospital Research Institute
High Risk Prostate Carcinoma
Towards Optimal Treatment for High Risk Prostate Cancer
The goal of this clinical trial is to combine several optimized treatments of high risk prostate cancer. The main question to answer is: is it safe to combine these optimized treatments.
- Trial name
- HYPOPRIME (NCT06204341)
- Testing
- HYPOPRIME treatment
- Where
- Netherlands
- Volunteers
- 207 people
- Sponsor
- Haaglanden Medical Centre